At a Glance
Dosage
Only in 1cP-MiPLA
oral
| Level | Dose |
|---|---|
| Threshold | 50 µg |
| Light | 100–150 µg |
| Common | 150–200 µg |
| Strong | 200–250 µg |
| Heavy | 300 µg |
Only in 25B-NBOMe
sublingual
| Level | Dose |
|---|---|
| Threshold | 50 µg |
| Light | 100–300 µg |
| Common | 300–500 µg |
| Strong |
Duration
Only in 1cP-MiPLA
oral
Total: 4 hrs – 6 hrsCome Up
Peak
Offset
Afterglow
Onset20 min – 40 min
Come Up45 min – 1.5 hrs
Peak1 hrs – 2 hrs
Offset1 hrs – 2 hrs
Effects
Safety
Interaction: 1cP-MiPLA + 25B-NBOMe
No direct interaction data available between these substances. This does not mean the combination is safe.
1cP-MiPLA — Dangerous Interactions
No dangerous interactions recorded.
25B-NBOMe — Dangerous Interactions
No dangerous interactions recorded.
Frequently Asked Questions
What is the difference between 1cP-MiPLA and 25B-NBOMe?
1cP-MiPLA is classified as a Psychedelic (Lysergamides) while 25B-NBOMe is classified as a Psychedelic (Substituted phenethylamines). They share 36 effects in common, with 34 effects unique to 1cP-MiPLA and 6 unique to 25B-NBOMe.
Is it safe to combine 1cP-MiPLA and 25B-NBOMe?
There is no direct interaction data available for combining 1cP-MiPLA and 25B-NBOMe. This does not mean the combination is safe. Always exercise caution and research thoroughly.
Which is stronger, 1cP-MiPLA or 25B-NBOMe?
1cP-MiPLA and 25B-NBOMe are typically administered via different routes, making a direct potency comparison difficult. They belong to different pharmacological profiles and should not be compared by dose alone.